Adjuvant formulations and their mode of action. NLM AIDSLINE Important note: Information in this article was accurate in 1992. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Adjuvant formulations and their mode of action.

Semin Immunol. 1990 Sep;2(5):369-74. Unique Identifier : AIDSLINE MED/92182252
Allison AC; Byars NE; Syntech Research, Palo Alto, CA 94304.

Abstract: We have developed an adjuvant formulation (SAF) consisting of a synthetic muramyl dipeptide analogue (N-acetylmuramyl-L-threonyl-D-isoglutamine) in a squalane-Pluronic polymer emulsion. Used with a variety of antigens SAF elicits cell-mediated immunity and antibodies of protective isotypes (IgG2a in the mouse). SAF augments responses to influenza virus haemagglutinin and hepatitis B virus surface antigen. Vaccines using SAF have protected guinea pigs against genital herpes simplex virus infections and subhuman primates against Epstein-Barr virus and simian immunodeficiency virus infections. Properties of SAF are compared with those of other adjuvants, including lipopolysaccharide analogs, ISCOMs and liposomes.
Keywords: Acetylmuramyl-Alanyl-Isoglutamine/*ANALOGS & DERIVATIVES/ IMMUNOLOGY *Adjuvants, Immunologic/CHEMISTRY Animal Antigens, Viral/*IMMUNOLOGY Emulsions Guinea Pigs Haplorhini Hepatitis B Virus/IMMUNOLOGY Herpesvirus 4, Human/IMMUNOLOGY Immunity, Cellular *Immunotherapy, Active Mice Orthomyxoviridae/IMMUNOLOGY Simplexvirus/IMMUNOLOGY SIV/IMMUNOLOGY Vaccines/*IMMUNOLOGY JOURNAL ARTICLEKWDacetylmuramyl-alanyl-isoglutamine/KWDanalogs&derivatives/immunologyKWDadjuvants,immunologic/chemistryanimalantigens,viral/KWDimmunologyemulsionsguineapigshaplorhinihepatitisbvirus/immunologyherpesvirus4,human/immunologyimmunity,cellularKWDimmunotherapy,activemiceorthomyxoviridae/immunologysimplexvirus/immunologysiv/immunologyvaccines/KWDimmunologyjournalarticle
920630
M9260991

Copyright © 1992 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1992. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1992. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .